Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Insufficiency, with a Focus on Postthrombotic Syndrome: A Narrative Review

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2021 May 24

PMID 34027293

Citations 1

Authors

Ke Xuan Li

Gisele Diendere

Jean-Philippe Galanaud

Nada Mahjoub

Susan R Kahn

Affiliations

Soon will be listed here.

Abstract

Introduction: Postthrombotic syndrome (PTS) is a form of secondary chronic venous insufficiency (CVI) that occurs after deep vein thrombosis (DVT). Effective treatments for PTS are lacking. Micronized purified flavonoid fraction (MPFF) is a venoactive drug used in the treatment of CVI.

Objective: To determine whether MPFF is a good candidate to explore as a therapeutic agent for PTS.

Methods: We performed a narrative review in which we identified 14 systematic reviews, 33 randomized controlled trials, and 19 observational studies that discussed the use of MPFF in CVI, as well as studies that reported on the mechanistic action of MPFF in relation to the pathophysiology of PTS.

Results: MPFF targets a number of pathophysiologic components of PTS. Based on animal models and human studies investigating objective vascular and lymphatic measures, MPFF promotes venous recanalization after DVT, decreases venous remodeling and reflux, inhibits inflammatory processes, improves venous tone and stasis, improves lymphatic circulation, improves capillary hyperpermeability, and decreases tissue hypoxia. Furthermore, MPFF shows promise in improving clinical manifestations, quality of life, and objective venous parameters of CVI. Studies suggest good patient acceptability and tolerability with the use of MPFF in CVI.

Conclusion: MPFF is a good candidate to explore as a potential therapy for PTS. Confirmatory high-quality studies are still needed to reinforce the evidence supporting the use of MPFF in CVI. Double-blind randomized controlled trials with clinical endpoints are needed to assess the clinical efficacy of MPFF in the treatment of PTS.

Citing Articles

The Synthetic Flavonoid Hidrosmin Improves Endothelial Dysfunction and Atherosclerotic Lesions in Diabetic Mice.

Jimenez-Castilla L, Opazo-Rios L, Marin-Royo G, Orejudo M, Rodrigues-Diez R, Ballesteros-Martinez C Antioxidants (Basel). 2022; 11(12).

PMID: 36552707 PMC: 9774734. DOI: 10.3390/antiox11122499.

References

Sonkin I, Shaidakov E, Krylov D, Bulatov V, Remizov A, Rezvantsev M . [Efficacy of Venarus in treatment of patients with post-thrombotic disease of lower limbs]. Angiol Sosud Khir. 2014; 20(4):77-83. View

Ibegbuna V, Nicolaides A, Sowade O, Leon M, Geroulakos G . Venous elasticity after treatment with Daflon 500 mg. Angiology. 1997; 48(1):45-9. DOI: 10.1177/000331979704800108. View

Wittens C, Davies A, Baekgaard N, Broholm R, Cavezzi A, Chastanet S . Editor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015; 49(6):678-737. DOI: 10.1016/j.ejvs.2015.02.007. View

Belcaro G, Cesarone M, Bavera P, Ricci A, Renton S, Leon M . HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial. J Cardiovasc Pharmacol Ther. 2002; 7(3):139-45. DOI: 10.1177/107424840200700303. View

Notten P, Ten Cate-Hoek A, Arnoldussen C, Strijkers R, de Smet A, Tick L . Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol. 2019; 7(1):e40-e49. DOI: 10.1016/S2352-3026(19)30209-1. View

Dominguez C, Brautigam I, Gonzalez E, Gonzalez J, Nazco J, Valiente R . Therapeutic effects of hidrosmin on chronic venous insufficiency of the lower limbs. Curr Med Res Opin. 1992; 12(10):623-30. DOI: 10.1185/03007999209111529. View

Danielsson G, Jungbeck C, Peterson K, Norgren L . A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 2001; 23(1):73-6. DOI: 10.1053/ejvs.2001.1531. View

COSPITE M, Dominici A . Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989; 8(4 Suppl):61-5. View

Prandoni P . Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol. 2011; 88(3):185-94. DOI: 10.1111/j.1600-0609.2011.01733.x. View

10.

Jantet G . RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology. 2000; 51(1):31-7. DOI: 10.1177/000331970005100107. View

11.

Cesarone M, Belcaro G, Rohdewald P, Pellegrini L, Ledda A, Vinciguerra G . Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost. 2006; 12(2):205-12. DOI: 10.1177/107602960601200209. View

12.

Amato C . Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin. Angiology. 1994; 45(6 Pt 2):531-6. View

13.

Allegra C, Bartolo Jr M, Carioti B, Cassiani D . An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency. Int J Microcirc Clin Exp. 1995; 15 Suppl 1:50-4. DOI: 10.1159/000179096. View

14.

Bogachev V, Boldin B, Turkin P . Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1. Adv Ther. 2018; 35(7):1001-1008. PMC: 11343914. DOI: 10.1007/s12325-018-0731-z. View

15.

Kakkos S, Nicolaides A . Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled.... Int Angiol. 2018; 37(2):143-154. DOI: 10.23736/S0392-9590.18.03975-5. View

16.

Iablokov E, Bogachev V, Domoradskaia A . [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)]. Ter Arkh. 1996; 68(10):80-1. View

17.

Mansilha A, Sousa J . Benefits of venoactive drug therapy in surgical or endovenous treatment for varicose veins: a systematic review. Int Angiol. 2019; 38(4):291-298. DOI: 10.23736/S0392-9590.19.04216-0. View

18.

Sirotin B, Zhmerenetski K . [Microcirculation end effect of detralex in patients with chronic venous insufficiency of the lower extremities]. Angiol Sosud Khir. 2003; 9(3):60-5. View

19.

Behar A, LAGRUE G, Cohen-Boulakia F, BAILLET J . Study of capillary filtration by double labelling I131-albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg. Int Angiol. 1988; 7(2 Suppl):35-8. View

20.

Bogachev V, Golovanova O, Kuzhetsov A, Shekoian A . [On advisability of perioperative phleboprotection in endovascular treatment of lower in varicose disease: first initial results of the decision study]. Angiol Sosud Khir. 2012; 18(2):90-5. View